var data={"title":"Interferon alfa-2b: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Interferon alfa-2b: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6375?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=interferon-alfa-2b-patient-drug-information\" class=\"drug drug_patient\">see &quot;Interferon alfa-2b: Patient drug information&quot;</a> and <a href=\"topic.htm?path=interferon-alfa-2b-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Interferon alfa-2b: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708923\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neuropsychiatric disorders:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Alpha interferons, including interferon alfa-2b, cause or aggravate fatal or life-threatening neuropsychiatric disorders. Monitor patients closely with periodic clinical and laboratory evaluations. Withdraw therapy from patients with persistently severe or worsening signs or symptoms of these conditions. In many but not all cases these disorders resolve after stopping interferon alfa-2b therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Autoimmune disorders:  </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Alpha interferons, including interferon alfa-2b, cause or aggravate fatal or life-threatening autoimmune disorders. Monitor patients closely with periodic clinical and laboratory evaluations. Withdraw therapy from patients with persistently severe or worsening signs or symptoms of these conditions. In many but not all cases these disorders resolve after stopping interferon alfa-2b therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Ischemic disorders:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Alpha interferons, including interferon alfa-2b, cause or aggravate fatal or life-threatening ischemic disorders. Monitor patients closely with periodic clinical and laboratory evaluations. Withdraw therapy from patients with persistently severe or worsening signs or symptoms of these conditions. In many but not all cases these disorders resolve after stopping interferon alfa-2b therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Infectious disorders:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Alpha interferons, including interferon alfa-2b, cause or aggravate fatal or life-threatening  infectious disorders. Monitor patients closely with periodic clinical and laboratory evaluations. Withdraw therapy from patients with persistently severe or worsening signs or symptoms of these conditions. In many but not all cases these disorders resolve after stopping interferon alfa-2b therapy.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183204\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Intron A</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183205\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Intron A</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183227\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Biological Response Modulator;</li>\n      <li>\n        Biological Response Modulator;</li>\n      <li>\n        Immunomodulator, Systemic;</li>\n      <li>\n        Interferon</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183207\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Consider premedication with acetaminophen prior to administration to reduce the incidence of some adverse reactions. Not all dosage forms and strengths are appropriate for all indications; refer to product labeling for details. Interferon alfa-2b at doses &ge;10 million units/m<sup>2</sup> is associated with a moderate emetic potential; antiemetics may be recommended to prevent nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hairy cell leukemia:</b> IM, SubQ: 2 million units/m<sup>2</sup> 3 times weekly for up to 6 months (may continue treatment with sustained treatment response); discontinue for disease progression or failure to respond after 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lymphoma (follicular):</b> SubQ: 5 million units 3 times weekly for up to 18 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malignant melanoma:</b> Induction: 20 million units/m<sup>2</sup> IV for 5 consecutive days per week for 4 weeks, followed by maintenance dosing of 10 million units/m<sup>2</sup> SubQ 3 times weekly for 48 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>AIDS-related Kaposi sarcoma:</b> IM, SubQ: 30 million units/m<sup>2</sup> 3 times weekly; continue until disease progression or until maximal response has been achieved after 16 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis B:</b> IM, SubQ: 5 million units daily or 10 million units 3 times weekly for 16 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis C:</b> IM, SubQ: 3 million units 3 times weekly. In patients with normalization of ALT at 16 weeks, continue treatment (if tolerated) for 18-24 months; consider discontinuation if normalization does not occur at 16 weeks. <b>Note:</b> May be used in combination therapy with ribavirin in previously untreated patients or in patients who relapse following alpha interferon therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Condyloma acuminata:</b> Intralesionally: 1 million units/lesion (maximum: 5 lesions per treatment) 3 times weekly (on alternate days) for 3 weeks. May administer a second course at 12-16 weeks.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183218\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=interferon-alfa-2b-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Interferon alfa-2b: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Consider premedication with acetaminophen prior to administration to reduce the incidence of some adverse reactions. Not all dosage forms and strengths are appropriate for all indications; refer to product labeling for details.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> The following dosing may also be used in <b>infants</b> in the setting of HIV-exposure/-infection (CDC 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis B (including HIV coinfection):</b> SubQ: Children and Adolescents 1 to 17 years: 3 million units/m<sup>2</sup> 3 times weekly for 1 week, followed by 6 million units/m<sup>2</sup> 3 times weekly (maximum: 10 million units per dose); total duration of therapy 16 to 24 weeks (treat for 24 weeks in HIV-exposure/-infection)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis C with HIV coinfection:</b> IM, SubQ: Children and Adolescents 1 to 17 years: 3 to 5 million units/m<sup>2</sup> 3 times weekly (maximum: 3 million units per dose) with ribavirin for 48 weeks, regardless of HCV genotype (CDC 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183208\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F249801\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Renal impairment at treatment initiation:</b> Combination therapy with ribavirin (hepatitis C) is contraindicated in patients with CrCl &lt;50 mL/minute; use combination therapy with ribavirin (hepatitis C) with caution in patients with impaired renal function and CrCl &ge;50 mL/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Renal toxicity during treatment:</b> <i>Indication-specific adjustments:</i> Lymphoma (follicular): Serum creatinine &gt;2 mg/dL: Permanently discontinue.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15897897\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hepatic impairment at treatment initiation:</b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Contraindicated in patients with decompensated liver disease or autoimmune hepatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Hepatotoxicity during treatment: </b> Permanently discontinue for severe (grade 3) hepatic injury or hepatic decompensation (Child-Pugh class B and C [score &gt;6]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">\n      <i>Indication-specific adjustments: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Lymphoma (follicular): AST &gt;5 times ULN: Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Malignant melanoma (induction and maintenance):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">ALT/AST &gt;5 to 10 times ULN: Temporarily withhold; resume with a 50% dose reduction when adverse reaction abates</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">ALT/AST &gt;10 times ULN: Permanently discontinue.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183228\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic toxicity (also refer to indication specified adjustments below): ANC &lt;500/mm<sup>3</sup> or platelets &lt;25,000/mm<sup>3</sup>: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity reaction (acute, serious), ophthalmic disorders (new or worsening), thyroid abnormality development (which cannot be normalized with medication), signs or symptoms of liver failure: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liver function abnormality, pulmonary infiltrate development, evidence of pulmonary function impairment, or autoimmune disorder development, triglycerides &gt;1,000 mg/dL: Monitor closely and discontinue if appropriate. Permanently discontinue for severe (grade 3) hepatic injury or hepatic decompensation (Child-Pugh class B and C [score &gt;6]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuropsychiatric disorders (during treatment):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Clinical depression or other psychiatric problem:</i> Monitor closely during and for 6 months after treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Severe depression or other psychiatric disorder:</i> Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Persistent or worsening psychiatric symptoms, suicidal ideation, aggression towards others:</i> Discontinue treatment and follow with appropriate psychiatric intervention.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Manufacturer-recommended adjustments, listed according to indication:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Lymphoma (follicular): </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neutrophils &gt;1000/mm<sup>3</sup> to &lt;1,500/mm<sup>3</sup>: Reduce dose by 50%; may re-escalate to starting dose when neutrophils return to &gt;1,500/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe toxicity (neutrophils &lt;1000/mm<sup>3</sup> or platelets &lt;50,000/mm<sup>3</sup>): Temporarily withhold.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AST &gt;5 times ULN or serum creatinine &gt;2 mg/dL: Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hairy cell leukemia:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Platelet count &lt;50,000/mm<sup>3</sup>: Do not administer intramuscularly (administer SubQ instead).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe toxicity: Reduce dose by 50% or temporarily withhold and resume with 50% dose reduction; permanently discontinue if persistent or recurrent severe toxicity is noted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Chronic hepatitis B</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">WBC &lt;1,500/mm<sup>3</sup>, granulocytes &lt;750/mm<sup>3</sup>, or platelet count &lt;50,000/mm<sup>3</sup>, or other laboratory abnormality or severe adverse reaction: Reduce dose by 50%; may re-escalate to starting dose upon resolution of hematologic toxicity. Discontinue for persistent intolerance.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">WBC &lt;1,000/mm<sup>3</sup>, granulocytes &lt;500/mm<sup>3</sup>, or platelet count &lt;25,000/mm<sup>3</sup>: Permanently discontinue</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Chronic hepatitis C:</i> Severe toxicity: Reduce dose by 50% or temporarily withhold until subsides; permanently discontinue for persistent toxicities after dosage reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>AIDS-related Kaposi sarcoma:</i> Severe toxicity: Reduce dose by 50% or temporarily withhold; may resume at reduced dose with toxicity resolution; permanently discontinue for persistent/recurrent toxicities.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Malignant melanoma (induction and maintenance): </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe toxicity including neutrophils &gt;250/mm<sup>3</sup> to &lt;500/mm<sup>3</sup> or ALT/AST &gt;5 to 10 times ULN: Temporarily withhold; resume with a 50% dose reduction when adverse reaction abates.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neutrophils &lt;250/mm<sup>3</sup>, ALT/AST &gt;10 times ULN, or severe/persistent adverse reactions: Permanently discontinue.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183183\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intron A: 6,000,000 units/mL (3.8 mL); 10,000,000 units/mL (3.2 mL) [contains edetate disodium, metacresol, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intron A: 10,000,000 units (1 ea); 18,000,000 units (1 ea); 50,000,000 units (1 ea) [contains albumin human]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183168\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50337642\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution, Injection:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intron A: 10,000,000 units/mL (1 mL, 2.5 mL) [contains edetate disodium, metacresol, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution, Injection (prefilled pen):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intron A: 6,000,000 units/mL (3 mL); 15,000,000 units/mL (1.2 mL); 25,000,000 units/mL (1.2 mL); 50,000,000 units/mL (1.2 mL) [contains edetate disodium, metacresol, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874825\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm111337.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9UPgXiAK20QB1EgZj8b1kxqINseuDYlFC+MACUFgnUbQ==&amp;TOPIC_ID=8563\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm111337.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183186\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer dose in the evening (if possible) to enhance tolerability. Not all dosage forms are recommended for all administration routes; refer to manufacturer&rsquo;s labeling. Interferon alfa-2b at doses &ge;10 million units/m<sup>2</sup> is associated with a moderate emetic potential; antiemetics may be recommended to prevent nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">IM: Rotate injection sites; preferred sites for injection are anterior thigh, deltoid, and superolateral buttock. Some patients may be appropriate for self-administration with appropriate training.  Allow to reach room temperature prior to injection. In hairy cell leukemia treatment, if platelets are &lt;50,000/mm<sup>3</sup>, do not administer intramuscularly (administer SubQ instead).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse over ~20 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: Suggested for those who are at risk for bleeding or are thrombocytopenic. Rotate SubQ injection site; preferred sites for injection are abdomen (except around the navel), anterior thigh, and outer upper arm. Patient should be well hydrated. Some patients may be appropriate for self-administration with appropriate training. Allow to reach room temperature prior to injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intralesional: Inject at an angle nearly parallel to the plane of the skin, directing the needle to center of the base of the wart to infiltrate the lesion core and cause a small wheal. Only infiltrate the keratinized layer; avoid administration which is too deep or shallow. Allow to reach room temperature prior to injection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183184\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>AIDS-related Kaposi sarcoma:</b> Treatment of patients 18 years and older with AIDS-related Kaposi sarcoma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis B:</b> Treatment of chronic hepatitis B in patients 1 year and older with compensated liver disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis C:</b> Treatment of chronic hepatitis C in patients 18 years and older with compensated liver disease who have a history of blood or blood-product exposure and/or are hepatitis C virus (HCV) antibody-positive; in combination with ribavirin for treatment of chronic hepatitis C in patients 3 years and older with compensated liver disease previously untreated with alpha interferon therapy and in patients 18 years and older who have relapsed following alpha interferon therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Condylomata acuminata:</b> Treatment of patients 18 years and older with condylomata acuminata involving external surfaces of the genital and perianal areas</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Follicular lymphoma:</b> Initial treatment of clinically aggressive follicular non-Hodgkin lymphoma in conjunction with anthracycline-containing combination chemotherapy in patients 18 years and older</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hairy cell leukemia:</b> Treatment of patients 18 years and older with hairy cell leukemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Melanoma (malignant):</b> Adjuvant to surgical treatment in patients 18 years and older with malignant melanoma who are free of disease but at high risk for systemic recurrence, within 56 days of surgery</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25726543\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Polycythemia vera; Chronic myelogenous leukemia (CML); Cutaneous T-cell lymphoma; Cutaneous ulcerations of Beh&ccedil;et's disease; Desmoid tumor; Hepatitis D;  Multiple myeloma; Neuroendocrine tumors (including carcinoid syndrome and islet cell tumor);  Non-Hodgkin lymphomas (other than follicular lymphoma, see approved use); Renal cell carcinoma; West Nile virus</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183238\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Interferon alfa-2b may be confused with interferon alfa-2a, interferon alfa-n3, pegylated interferon alfa-2b, peginterferon beta-1a</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intron A may be confused with PEG-Intron</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Interferon alfa-2b may be confused with interferon alpha multi-subtype which is available in international markets</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183175\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> In a majority of patients, a flu-like symptom (fever, chills, tachycardia, malaise, myalgia, headache), occurs within 1 to 2 hours of administration; may last up to 24 hours and may be dose limiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (&le;28%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (8% to 96%), headache (21% to 62%), chills (&le;54%), rigors (&le;42%), depression (3% to 40%; grades 3/4: 2%), drowsiness (&le;33%), dizziness (&le;24%), irritability (&le;22%), paresthesia (1% to 21%), pain (&le;18%), right upper quadrant pain (&le;15%), amnesia (&le;14%), lack of concentration (&le;14%), malaise (&le;14%), confusion (&le;12%), insomnia (&le;12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (&le;38%), skin rash (&le;25%), diaphoresis (1% to 21%), pruritus (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (&le;13%), amenorrhea (&le;12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia (1% to 69%), nausea (17% to 66%), diarrhea (2% to 45%), vomiting (children 27%; adults 2% to 32%), xerostomia (&le;28%), dysgeusia (&le;24%), abdominal pain (&le;23%), constipation (&le;14%), gingivitis (&le;14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Neutropenia (&le;92%; grade 4: 1% to 4%), leukopenia (&le;68%), anemia (&le;32%), thrombocytopenia (&le;15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum AST (&le;63%; grades 3/4: 14%), increased serum ALT (&le;15%), increased serum alkaline phosphatase (&le;13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Candidiasis (&le;17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (&le;20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (16% to 75%), weakness (&le;63%), musculoskeletal pain (&le;21%), arthralgia (&le;19%), back pain (&le;19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased blood urea nitrogen (&le;12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Flu-like symptoms (&le;79%), dyspnea (&le;34%), cough (&le;31%), pharyngitis (&le;31%), sinusitis (&le;21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (34% to 94%; more common in children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (&le;9%), edema (&le;5%), angina pectoris (&lt;5%), arteritis (&lt;5%), atrial fibrillation (&lt;5%), bradycardia (&lt;5%), cardiac arrhythmia (&lt;5%), cardiac failure (&lt;5%), cardiomegaly (&lt;5%), cardiomyopathy (&lt;5%), cerebrovascular accident (&lt;5%), coronary artery disease (&lt;5%), extrasystoles (&lt;5%), flushing (&lt;5%), heart valve disease (&lt;5%), hypotension (&lt;5%), palpitations (&lt;5%), periarteritis nodosa (&lt;5%), peripheral ischemia (&lt;5%), pulmonary embolism (&lt;5%), Raynaud phenomenon (&lt;5%), syncope (&lt;5%), tachycardia (&lt;5%), thrombosis (&lt;5%), facial edema (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Hypoesthesia (&le;10%), anxiety (&le;9%), vertigo (&le;8%), agitation (&le;7%), aggressive behavior (&lt;5%), aphasia (&lt;5%), ataxia (&lt;5%), Bell palsy (&lt;5%), carpal tunnel syndrome (&lt;5%), coma (&lt;5%), dysphasia (&lt;5%), extrapyramidal reaction (&lt;5%), hyporeflexia (&lt;5%), hypothermia (&lt;5%), manic depressive reaction (&lt;5%), manic reaction (&lt;5%), migraine (&lt;5%), neuralgia (&lt;5%), neuropathy (&lt;5%), nightmares (&lt;5%) psychoneurosis (&lt;5%), psychosis (&lt;5%), seizure (&lt;5%), suicidal ideation (&lt;5%), nervousness (&le;3%), hallucination, homicidal ideation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Xeroderma (&le;10%), dermatitis (&le;8%), cellulitis (&lt;5%), eczema (&lt;5%), epidermal cyst (sebaceous) (&lt;5%), erythema (&lt;5%), erythema nodosum (&lt;5%), erythematous rash (&lt;5%), exacerbation of psoriasis (&lt;5%), folliculitis (&lt;5%), furunculosis (&lt;5%), lichenoid dermatitis (&lt;5%), lipoma (&lt;5%), maculopapular rash (&lt;5%), psoriasis (&lt;5%), skin photosensitivity (&lt;5%), toxic epidermal necrolysis (&lt;5%), urticaria (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Decreased libido (&le;5%), albuminuria (&lt;5%), dehydration (&lt;5%), diabetes mellitus (&lt;5%), goiter (&lt;5%), hirsutism (&lt;5%), hot flash (&lt;5%), hypercalcemia (&lt;5%), hyperglycemia (&lt;5%), hyperthyroidism (&lt;5%), hypertriglyceridemia (&lt;5%), hypothyroidism (&lt;5%), menorrhagia (&lt;5%), increased lactate dehydrogenase (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Loose stools (&le;10%), dyspepsia (&le;8%), aphthous stomatitis (&lt;5%), biliary colic (&lt;5%), colitis (&lt;5%), esophagitis (&lt;5%), gastritis (&lt;5%), gastrointestinal hemorrhage (&lt;5%), mucositis (&lt;5%), stomatitis (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (&le;5%), cystitis (&lt;5%), dysuria (&lt;5%), hematuria (&lt;5%), impotence (&lt;5%), leukorrhea (&lt;5%), mastitis (&lt;5%), nocturia (&lt;5%), pelvic pain (&lt;5%), proteinuria (&lt;5%), sexual disorder (&lt;5%), urinary incontinence (&lt;5%), uterine hemorrhage (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Purpura (&le;5%), granulocytopenia (&lt;5%), hemolytic anemia (&lt;5%), hypochromic anemia (&lt;5%), lymphadenitis (&lt;5%), lymphadenopathy (&lt;5%), lymphocytosis (&lt;5%), rectal hemorrhage (&lt;5%), lipoma</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal hepatic function tests (&lt;5%), ascites (&lt;5%), hepatic encephalopathy (&lt;5%), hepatic failure (&lt;5%), hepatitis (&lt;5%), hepatotoxicity (including idiosyncratic; &lt;5%), hyperbilirubinemia (&lt;5%), jaundice (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (&le;7%), herpes virus infection (&le;5%), abscess (&lt;5%), fungal infection (&lt;5%), sepsis (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Amyotrophy (&lt;5%), arthritis (&lt;5%), leg cramps (&lt;5%), rheumatoid arthritis (&lt;5%), spondylitis (&lt;5%), tendonitis (&lt;5%), tremor (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (&lt;5%), conjunctivitis (&lt;5%), nystagmus (&lt;5%), photophobia (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Auditory impairment (&lt;5%), hearing loss (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Polyuria (&le;10%), increased serum creatinine (&le;6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis (&le;10%), nasal congestion (&le;10%), epistaxis (&le;7%), asthma (&le;5%), bronchospasm (&le;5%), cyanosis (&le;5%), hemoptysis (&le;5%), hypoventilation (&le;5%), pleural effusion (&le;5%), pneumonia (&le;5%), pneumothorax (&le;5%), respiratory insufficiency (&le;5%), wheezing (&le;5%), upper respiratory tract infection (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Alcohol intolerance (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, aplastic anemia, bronchiolitis obliterans, bronchoconstriction, erythema multiforme, exacerbation of sarcoidosis, hallucination, homicidal ideation, hypersensitivity reaction (acute), immune thrombocytopenia, interstitial pneumonitis, macular edema, myocardial infarction, myositis, nephrotic syndrome, optic neuritis, pancreatitis, pancytopenia, papilledema, pericarditis, peripheral neuropathy, pituitary insufficiency, pulmonary fibrosis, pulmonary hypertension, pulmonary infiltrates, pure red cell aplasia, reactivation of HBV, reduced ejection fraction, renal failure, renal insufficiency, retinal cotton-wool spot, retinal detachment (serous), retinal thrombosis, rhabdomyolysis, sarcoidosis, Stevens-Johnson syndrome, systemic lupus erythematosus, thrombotic thrombocytopenic purpura, tissue necrosis at injection site, vasculitis, Vogt-Koyanagi-Harada syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183189\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to interferon alfa or any component of the formulation; decompensated liver disease; autoimmune hepatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Combination therapy with interferon alfa-2b and ribavirin is also contraindicated in women who are pregnant, in males with pregnant partners; in patients with hemoglobinopathies (eg, thalassemia major, sickle-cell anemia); creatinine clearance &lt;50 mL/minute; or hypersensitivity to ribavirin or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Documentation of allergenic cross-reactivity for interferons is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183172\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Causes bone marrow suppression, including potentially severe cytopenias, and very rarely, aplastic anemia. Discontinue treatment for severe neutropenia (ANC &lt;500/mm<sup>3</sup>) or thrombocytopenia (platelets &lt;25,000/mm<sup>3</sup>). Hemolytic anemia (hemoglobin &lt;10 g/dL) was observed in ~10% of treated patients in clinical trials when combined with ribavirin; anemia occurred within 1 to 2 weeks of initiation of therapy. Use caution in patients with preexisting myelosuppression and in patients with concomitant medications which cause myelosuppression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular events: Hemorrhagic and ischemic cerebrovascular events have been observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dental and periodontal disorders: In patients receiving combination interferon and ribavirin therapy, dental and periodontal disorders have been reported; additionally, dry mouth can damage teeth and mouth mucous membranes during chronic therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Flu-like symptoms: Commonly associated with fever and flu-like symptoms; rule out other causes/infections with persistent fever. Use with caution in patients with debilitating conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Interferon alfa-2b at doses &ge;10 million units/m<sup>2</sup> is associated with a moderate emetic potential; antiemetics may be recommended to prevent nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: May cause hepatotoxicity (including fatality); monitor closely if abnormal liver function tests develop. A transient increase in ALT (&ge;2 times baseline) may occur in patients treated with interferon alfa-2b for chronic hepatitis B. Therapy generally may continue, however, functional indicators (eg, albumin, prothrombin time, bilirubin) should be monitored frequently. Worsening and potentially fatal liver disease, including jaundice, hepatic encephalopathy, and hepatic failure have been reported in patients receiving interferon alfa for chronic hepatitis B and C with decompensated liver disease, autoimmune hepatitis, history of autoimmune disease, and immunosuppressed transplant recipients; avoid interferon treatment (if appropriate) in these patients (use is contraindicated in decompensated liver disease). Patients with cirrhosis are at increased risk of hepatic decompensation. Therapy should be discontinued for any patient developing signs and symptoms of liver failure. Permanently discontinue for severe (grade 3) hepatic injury or hepatic decompensation (Child-Pugh class B and C [score &gt;6]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Acute hypersensitivity reactions (eg, urticaria, angioedema, bronchoconstriction, anaphylaxis) have been reported (rarely) with alfa interferons. If an acute reaction develops, discontinue therapy immediately; transient rashes have occurred in some patients following injection, but have not necessitated treatment interruption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertriglyceridemia: Has been reported (discontinue if persistent and severe, particularly if combined with symptoms of pancreatitis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropsychiatric disorders: <b>[US Boxed Warning]: May cause or aggravate severe neuropsychiatric adverse events; monitor closely with clinical evaluations (periodic); discontinue treatment for severe persistent or worsening symptoms; some cases may resolve with discontinuation.</b> Psychiatric events may include depression psychosis, mania, suicidal ideation, suicide attempts, completed suicides, and homicidal ideation may occur in patients with or without previous psychiatric symptoms. Effects are usually rapidly reversible upon therapy discontinuation, but have persisted up to 3 weeks. If psychiatric symptoms persist or worsen, or suicidal or homicidal ideation or aggressive behavior towards others is identified, discontinue treatment and follow the patient closely. Careful neuropsychiatric monitoring is recommended during and for 6 months after treatment in patients who develop psychiatric disorders (including clinical depression). New or exacerbated neuropsychiatric or substance abuse disorders are best managed with early intervention. Use with caution in patients with a history of psychiatric disorders. Drug screening and periodic health evaluation (including monitoring of psychiatric symptoms) is recommended if initiating treatment in patients with coexisting psychiatric condition or substance abuse disorders. Suicidal ideation or attempts may occur more frequently in pediatric patients (eg, adolescents) when compared to adults. Higher doses, usually in elderly patients, may result in increased CNS toxicity (eg, obtundation and coma).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: Decreased or loss of vision, macular edema, optic neuritis, retinal hemorrhages, cotton wool spots, papilledema, retinal detachment (serous), and retinal artery or vein thrombosis have occurred (or been aggravated) in patients receiving alfa interferons. Use caution in patients with preexisting eye disorders; monitor closely; a complete eye exam should be done promptly in patients who develop ocular symptoms; discontinue with new or worsening ophthalmic disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary effects: Dyspnea, pulmonary infiltrates, pulmonary hypertension, interstitial pneumonitis, pneumonia, bronchiolitis obliterans, and sarcoidosis may be induced or aggravated by treatment, sometimes resulting in respiratory failure or fatality. Has been reported more in patients being treated for chronic hepatitis C, although has also occurred with use for oncology indications. Patients with fever, cough, dyspnea or other respiratory symptoms should be evaluated with a chest x-ray; monitor closely and consider discontinuing treatment with evidence of impaired pulmonary function. Use with caution in patients with a history of pulmonary disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; AIDS-related Kaposi sarcoma: Do not treat patients with visceral AIDS-related Kaposi sarcoma associated with rapidly-progressing or life-threatening disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune disease: <b>[US Boxed Warning]: May cause or aggravate fatal or life-threatening autoimmune disorders; monitor closely with clinical and laboratory evaluations (periodic); discontinue treatment for severe persistent or worsening symptoms; some cases may resolve with discontinuation. </b> Autoimmune disorders (thrombocytopenia, vasculitis, Raynaud disease, rheumatoid arthritis, lupus erythematosus and rhabdomyolysis) have been associated with alfa interferons. Worsening of psoriasis and sarcoidosis (and the development of new sarcoidosis) have been reported; use caution in patients with these conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease; monitor closely in patients with cardiovascular disease (ischemic or thromboembolic), arrhythmias, hypertension, and in patients with a history of MI and/or prior therapy with cardiotoxic drugs. Patients with preexisting cardiac disease and/or advanced cancer should have baseline and periodic ECGs. May cause hypotension (during administration or delayed up to 2 days), arrhythmia, tachycardia (&ge; 150 bpm), cardiomyopathy (~2% in AIDS-related Kaposi sarcoma patients), and/or MI; some experiencing cardiovascular adverse effects had no prior history of cardiac disease. Supraventricular arrhythmias occur rarely, and are associated with preexisting cardiac disease or prior therapy with cardiotoxic agents. Dose modification, discontinuation and/or additional therapies may be necessary. In a scientific statement from the American Heart Association, interferon has been determined to be an agent that may either cause reversible direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate/major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic hepatitis: Patients being treated for chronic hepatitis B or C with a history of autoimmune disease or who are immunosuppressed transplant recipients should not receive interferon alfa-2b.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Coagulation disorders: Use with caution and monitor closely in patients with coagulation disorders (eg, thrombophlebitis, pulmonary embolism).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Has been reported; discontinue if diabetes cannot be effectively managed with medication. Use with caution in patients with a history of diabetes mellitus, particularly if prone to DKA.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infectious disorders: <b> [US Boxed Warning]: May cause or aggravate fatal or life-threatening infectious disorders; monitor closely with clinical and laboratory evaluations (periodic); discontinue treatment for severe persistent or worsening symptoms; some cases may resolve with discontinuation.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ischemic disorders:<b> [US Boxed Warning]: May cause or aggravate fatal or life-threatening ischemic disorders; monitor closely with clinical and laboratory evaluations (periodic); discontinue treatment for severe persistent or worsening symptoms; some cases may resolve with discontinuation.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary disorders: Use with caution and monitor closely in patients with pulmonary disorders (eg, COPD).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disorders: Use with caution in patients with preexisting thyroid disease; thyroid disorders (hyper- or hypothyroidism) have been reported. TSH levels should be within normal limits prior to initiating interferon; treatment should not be initiated in patients with preexisting thyroid disease who cannot be maintained in normal ranges by medication. Discontinue interferon use in patients who develop thyroid abnormalities during treatment and in patients with thyroid disease who subsequently cannot maintain normal ranges with thyroid medication. Discontinuation of interferon therapy may or may not reverse thyroid dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Combination therapy with ribavirin: Combination therapy with ribavirin is associated with birth defects and/or fetal mortality and hemolytic anemia. Do not use combination therapy with ribavirin in patients with creatinine clearance &lt;50 mL/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Albumin: Some formulations contain albumin, which may carry a remote risk of viral transmission, including a theoretical risk of Creutzfeldt-Jakob disease transmission.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product variability: <b>Due to differences in dosage, patients should not change brands of interferons without the concurrence of their health care provider. </b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183220\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP1A2 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183177\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8563&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Interferons (Alfa) may increase the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin (Oral Inhalation): Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin (Oral Inhalation). Hemolytic anemia has been observed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin (Systemic): Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin (Systemic). Hemolytic anemia has been observed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telbivudine: Interferon Alfa-2b may enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Interferons may decrease the metabolism of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible.  If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183179\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C / X in combination with ribavirin (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183191\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have demonstrated abortifacient effects. Disruption of the normal menstrual cycle was also observed in animal studies; therefore, the manufacturer recommends that reliable contraception is used in women of childbearing potential. Alfa interferon is endogenous to normal amniotic fluid. In vitro administration studies have reported that when administered to the mother, it does not cross the placenta. Case reports of use in pregnant women are limited. The Perinatal HIV Guidelines Working Group does not recommend that interferon-alfa be used during pregnancy. Interferon alfa-2b monotherapy should only be used in pregnancy when the potential benefit to the mother justifies the possible risk to the fetus. Combination therapy with ribavirin is contraindicated in pregnancy (refer to Ribavirin (Systemic) monograph); two forms of contraception should be used during combination therapy and patients should have monthly pregnancy tests. A pregnancy registry has been established for women inadvertently exposed to ribavirin while pregnant (800-593-2214). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183192\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Breast milk samples obtained from a lactating mother prior to and after administration of interferon alfa-2b showed that interferon alfa is present in breast milk and administration of the medication did not significantly affect endogenous levels. Breastfeeding is not linked to the spread of hepatitis C virus; however, if nipples are cracked or bleeding, breastfeeding is not recommended. Mothers coinfected with HIV are discouraged from breastfeeding to decrease potential transmission of HIV.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183181\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">General monitoring parameters for <i>all indications</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">At baseline (repeat during therapy if clinically indicated): Chest x-ray, serum creatinine, albumin, prothrombin time, triglycerides.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">At baseline and periodically thereafter: CBC with differential, platelets and hemoglobin, liver function tests, electrolytes and TSH; ophthalmic exam (or with new ocular symptoms); ECG (in patients with pre-existing cardiac abnormalities or in advanced stages of cancer). Monitor serum bilirubin, ALT, AST, alkaline phosphatase and LDH at 2, 8 and 12 weeks following initiation, then every 6 months during treatment. Permanently discontinue for severe (grade 3) hepatic injury or hepatic decompensation (Child-Pugh class B and C [score &gt;6]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">During therapy: Weight; neuropsychiatric changes during and for 6 months after therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Additional <i>indication-specific</i> monitoring parameters:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Chronic hepatitis B: CBC with differential and platelets and liver function tests: Baseline, weeks 1, 2, 4, 8, 12, and 16, at the end of treatment, and then 3 and 6 months post treatment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Chronic hepatitis C:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CBC with differential and platelets: Baseline, weeks 1 and 2, then monthly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Liver function: Every 3 months</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">TSH: Baseline and periodically during treatment; in patients with pre-existing thyroid disorders also repeat at 3 months and 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Condyloma acuminate (intralesional administration):  Monitor CBC with differential, liver function tests (elevations have been reported).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Malignant melanoma: CBC with differential and platelets and liver function tests: Weekly during induction phase, then monthly during maintenance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oncology patients: Thyroid function monitoring (Hamnvik 2011): TSH and anti-TPO antibodies at baseline; if TPO antibody positive, monitor TSH every 2 months; if TPO antibody negative, monitor TSH every 6 months</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183171\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to a specific receptor on the cell wall to initiate intracellular activity; multiple effects can be detected including induction of gene transcription. Inhibits cellular growth, alters the state of cellular differentiation, interferes with oncogene expression, alters cell surface antigen expression, increases phagocytic activity of macrophages, and augments cytotoxicity of lymphocytes for target cells</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183188\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 31 L; but has been noted to be much greater (370 to 720 L) in leukemia patients receiving continuous infusion IFN; IFN does not penetrate the CSF</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Primarily renal, filtered and absorbed at the renal tubule</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: IM: 83%; SubQ: 90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IV: ~2 hours; IM, SubQ: ~2 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: IM, SubQ: ~3 to 12 hours; IV: By the end of a 30-minute infusion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2524635\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Intron A Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6000000 units/mL (3.8 mL): $854.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10000000 units/mL (3.2 mL): $1,186.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Intron A Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10000000 unit (1): $368.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">18000000 unit (1): $663.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50000000 unit (1): $1,843.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183193\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bioferon (PY, TH, UY);</li>\n      <li>Enduferon (PH);</li>\n      <li>FNI 2B (MX);</li>\n      <li>Heberon Alfa R (CO);</li>\n      <li>Intron A (AE, AR, AT, AU, BB, BE, BH, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, FI, FR, GB, GR, GT, HK, HN, HR, HU, IL, IS, IT, JO, JP, KE, KW, LT, LU, MT, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PT, QA, RO, RU, SA, SE, SI, SK, SV, TR, TW, UA, VE, VN);</li>\n      <li>Intron-A (GR, ID, MY, SG);</li>\n      <li>Introna (AT, DK, ES, FI, FR, NO, SE);</li>\n      <li>IntronA (IE);</li>\n      <li>Kaifu (CN);</li>\n      <li>Peg-Intron (HK, KR);</li>\n      <li>Realdiron (BG);</li>\n      <li>Realfa (IN);</li>\n      <li>Reliferon (PH);</li>\n      <li>Viraferon (AT, BE, BG, CH, CZ, DE, DK, EE, FI, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Practice Bulletin No. 86: &ldquo;Viral Hepatitis in Pregnancy,&rdquo; <i>Obstet Gynecol</i>, 2007, 110(4):941-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/17906043/pubmed\" target=\"_blank\" id=\"17906043\">17906043</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28135150\"></a>Agarwala SS, Lee SJ, Yip W, et al. Phase III randomized study of 4 weeks of high-dose interferon-&alpha;-2b in stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) melanoma: a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). <i>J Clin Oncol</i>. 2017;35(8):885-892.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/28135150/pubmed\" target=\"_blank\" id=\"28135150\">28135150</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Atkins MB, Hsu J, Lee S, et al, &ldquo;Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group,&rdquo; <i>J Clin Oncol</i>, 2008, 26(35):5748-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/19001327/pubmed\" target=\"_blank\" id=\"19001327\">19001327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23803709\"></a>Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. <i>Blood</i>. 2013;122(6):872-884.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/23803709/pubmed\" target=\"_blank\" id=\"23803709\">23803709</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Balkwill FR and Smyth JF, &ldquo;Interferons in Cancer Therapy: A Reappraisal,&rdquo; <i>Lancet</i>, 1987, 2(8554):317-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Sexually Transmitted Diseases Treatment Guidelines, 2010,&quot; <i>MMWR Recomm Rep</i>, 2010, 59(RR-12):1-110.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/21160459/pubmed\" target=\"_blank\" id=\"21160459\">21160459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 12, 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, &quot;Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,&quot; July 31, 2012. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gresser I, &ldquo;Biologic Effects of Interferons,&rdquo; <i>J Invest Dermatol</i>, 1990, 95(6 Suppl):66-71.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo; <i>J Natl Cancer Inst</i>, 2011, 103(21):1572-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/22010182/pubmed\" target=\"_blank\" id=\"22010182\">22010182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Houglum JE, &ldquo;Interferon: Mechanisms of Action and Clinical Value,&rdquo; <i>Clin Pharm</i>, 1983, 2(1):20-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/6192965/pubmed\" target=\"_blank\" id=\"6192965\">6192965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Intron-A (interferon alfa-2b) [prescribing information]. Whitehouse Station, NJ: Schering Corporation; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Intron-A (interferon alfa-2b) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K&ouml;tter I, G&uuml;naydin I, Zierhut M, et al, &ldquo;The Use of Interferon Alpha in Beh&ccedil;et Disease: Review of the Literature,&quot; <i>Semin Arthritis Rheum</i>, 2004, 33(5):320-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/15079763/pubmed\" target=\"_blank\" id=\"15079763\">15079763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lebon P, Girard S, Thepot F, et al, &ldquo;The Presence of Alpha-Interferon in Human Amniotic Fluid,&rdquo; <i>J Gen Virol</i>, 1982, 59(Pt 2):393-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/6176680/pubmed\" target=\"_blank\" id=\"6176680\">6176680</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Legha SS, &ldquo;The Role of Interferon Alfa in the Treatment of Metastatic Melanoma,&rdquo; <i>Semin Oncol</i>, 1997, 24(1 Suppl 4):24-31.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Musselman DL, Lawson DH, Gumnick JF, et al, &ldquo;Paroxetine for the Prevention of Depression Induced by High-Dose Interferon Alfa,&rdquo; <i>N Engl J Med</i>, 2001, 344(13):961-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/11274622/pubmed\" target=\"_blank\" id=\"11274622\">11274622</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pectasides D, Dafni U, Bafaloukos D, et al, &ldquo;Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma,&rdquo; <i>J Clin Oncol</i>, 2009, 27(6):939-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/19139440/pubmed\" target=\"_blank\" id=\"19139440\">19139440</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tilg H, &ldquo;New Insights Into the Mechanisms of Interferon Alfa: An Immunoregulatory and Anti-Inflammatory Cytokine,&rdquo; <i>Gastroenterology</i>, 1997, 112(3):1017-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/9041265/pubmed\" target=\"_blank\" id=\"9041265\">9041265</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vial T and Descotes J, &ldquo;Clinical Toxicity of the Interferons,&rdquo; <i>Drug Saf</i>, 1994, 10(2):115-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/7516663/pubmed\" target=\"_blank\" id=\"7516663\">7516663</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Waysbort A, Giroux M, Mansat V, et al, &ldquo;Experimental Study of Transplacental Passage of Alpha Interferon by Two Assay Techniques,&rdquo; <i>Antimicrob Agents Chemother</i>, 1993, 37(6):1232-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/8328774/pubmed\" target=\"_blank\" id=\"8328774\">8328774</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wills RJ, &ldquo;Clinical Pharmacokinetics of Interferons,&rdquo; <i>Clin Pharmacokinet</i>, 1990, 19(5):390-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-drug-information/abstract-text/1702693/pubmed\" target=\"_blank\" id=\"1702693\">1702693</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8563 Version 153.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708923\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F183204\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F183205\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F183227\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F183207\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F183218\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F183208\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F249801\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15897897\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F183228\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F183183\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F183168\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F50337642\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874825\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F183186\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F183184\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25726543\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F183238\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F183175\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F183189\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F183172\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F183220\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F183177\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F183179\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F183191\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F183192\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F183181\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F183171\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F183188\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F2524635\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F183193\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8563|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=interferon-alfa-2b-patient-drug-information\" class=\"drug drug_patient\">Interferon alfa-2b: Patient drug information</a></li><li><a href=\"topic.htm?path=interferon-alfa-2b-pediatric-drug-information\" class=\"drug drug_pediatric\">Interferon alfa-2b: Pediatric drug information</a></li></ul></div></div>","javascript":null}